Austin, Texas, United States, August 25th, 2026, NewsDirect
- Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct the preclinical validation needed to determine the program’s next development steps.
- VXA-222 uses an “AND-gate” approach designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload.
- The company has separately filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms while expanding protection around antibody conjugation and payload technologies.
- The company is building a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has moved its VXA-222 bispecific antibody-drug conjugate program into the next stage of development after completing the initial phase of its collaboration with OmniAb, giving the biotechnology company a new development milestone while it continues expanding the intellectual-property estate underpinning its antibody technology portfolio.
According to a Yahoo Finance report, VERAXA will now take the antibody binders generated through the OmniAb collaboration and use its own antibody engineering, linker and conjugation technologies to construct the final…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Contact
IBN
www.InvestorBrandNetwork.com
[email protected]